DECABID
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DECABID is an oral extended-release tablet approved by Eli Lilly in 1989 as a small-molecule NDA. The mechanism of action and indications are not publicly specified in available data. Patient population cannot be determined without indication clarity.
LOE Approaching
Loss-of-exclusivity imminent; commercial team likely in defensive mode focused on managed care and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DECABID shows zero linked job openings, indicating a mature, minimal-staffing product in transition. Roles available are typically in customer retention, managed care negotiation, and competitive defense rather than growth or launch activities.
Brand ManagerField Sales Representative
Worked on DECABID at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.